Clinical Activity of IMA203CD8, a PRAMEDirected TCR T-Cell Therapy in Solid Tumors
- Targeting of PRAME across tumor types with IMA203CD8 leveraging both CD8+ and CD4+ T cells
- Sharing promising clinical results from a PRAME-directed TCR T-cell therapy including proof-of concept in ovarian cancer
- Discussing opportunities for tumor-agnostic development across a broad spectrum of PRAME expression levels